<DOC>
	<DOCNO>NCT02693652</DOCNO>
	<brief_summary>A single center , open label phase I/IIa study evaluate safety , tolerability efficacy therapeutic hepatitis B vaccine oral antiviral drug-treated chronic hepatitis B virus carrier</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Therapeutic Hepatitis B Vaccine</brief_title>
	<detailed_description>- Objectives : To explore appropriate dose therapeutic hepatitis B vaccine evaluation safety , tolerability , efficacy - Subjects : Chronic hepatitis B carrier normal ALT range - Study hypothesis : The immune tolerance break strong immune response chronic hepatitis B carrier could achieve therapeutic hepatitis B vaccine contain novel adjuvant</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>1 . Adult 19 60 year age 2 . Chronic hepatitis B carrier ( HBsAg positive 6 month ) 3 . HBeAg positive patient , patient lose HBeAg Antiviral drug treatment 4 . Antiviral drug treat patient reduce HBV DNA level 2000 IU/mL measure COBAS TaqManM HBV Test ( Duration drug administration 6 month limitation type antiviral drug ) 5 . Patient low ALT 1.1 fold upper limit normal ALT level screen 6 . Patient able provide write informed consent oneself legal representative 1 . Patient liver disease except chronic hepatitis B ( i.e . hematochromatosis , alcoholic liver disease , nonalcoholic fatty liver disease , alpha1 antitrypsin deficiency etc . ) 2 . Patient one test result symptom screen ALT &gt; upper limit normal level X 1.1 Total bilirubin &gt; upper limit normal Prothrombin time &gt; Over 3 second normal Serum Albumin &lt; 30 g/L ( 3 g/dL ) Patient history ascites , yellow jaundice , variceal hemorrhage , hepatic encephalopathy , liver failure Liver FibroScan &gt; F3 ( F0 : fibrosis , F1 : portal fibrosis , F2 : periportal fibrosis , F3 : septal fibrosis , F4 : cirrhosis ) 3 . Patient one test result screen Hemoglobin &lt; 9.0 g/dL Absolute neutrophil count ( ANC ) &lt; 1.5 x 109 /L ( 1500 /mm3 ) Platelet count &lt; 100 x 109 /L ( 100 x 103 /mm3 ) Serum creatinine &gt; 1.5 mg/dL Serum amylase &gt; 2 x ULN Lipase &gt; 2 x ULN 4 . Patient history Interferon treatment 5 . Patient pregnant breastfeeding intend become pregnant study 6 . Patient active microbial , viral , fungal infection need systemic treatment 7 . Alphafetoprotein ( AFP ) &gt; 50 ng/mL Hepatocellular Carcinoma ( HCC ) patient 8 . Among patient treat immunosuppressive drug within 6 month screen , suspected case decline immunity opinion investigator 9 . Patient long term systemic treatment ( 14 day consecutively ) high dose ( 20 mg prednisolone equivalent dose* ) corticosteroid ( Decision participate patient local treatment corticosteroid allow opinion investigator ) *equivalent cortisone 125 mg , hydrocortisone 100 mg , prednisone 20 mg , methylprednisolone 16 mg , triamcinolone 16 mg , dexamethasone 3 mg , betamethasone 2.4 mg 10 . Patient diagnose malignant tumor within 5 year screen relapsed patient ( Benign tumor patient able participate study discretion investigator ) 11 . Patient history organ transplantation 12 . Patient serious disease judge investigator heart failure , renal failure , pancreatitis 13 . Patient history serious heart disease ( NYHA Functional Class III IV heart failure , myocardial infarction within 6 month , treatment require ventricular tachyarrhythmias , unstable angina etc . ) 14 . Patient seizure disorder require anticonvulsant treatment 15 . Uncontrollable diabetic patient ( FBS &gt; 130mg/dl , HbA1c &gt; 7.5 % ) 16 . Uncontrollable hypertension patient ( SBP≥140mmHg 또는 DBP≥90mmHg ) 17 . HCV , HDV , HIV patient 18 . Patient plan participate clinical study , take part clinical study within 1 month enrollment 19 . Patient hypersensitivity anaphylactic reaction component investigational product HBV vaccine 20 . Patient continuous drinking ( &gt; 21 units/week , 1 unit = 10g pure alcohol ) dependence alcohol 21 . Patient concerned decline daily activity able understand objective method due psychiatric problem 22 . Patient potential severe febrile systemic reaction 23 . Subject unacceptable study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>